A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06840003 In Patients With Malignant Gliomas
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Feb 2018
At a glance
- Drugs EOS-200271 (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 09 Feb 2018 According to an iTeos Therapeutics Media Release, trial will be expanded in 2018.
- 28 Jan 2018 Status changed from suspended to active, no longer recruiting.
- 12 Jan 2018 Status changed from recruiting to suspended.